Neuralstem (AMEX: CUR) announced that two sets of data from the NSI-189 clinical trial in major depressive disorder (MDD) were ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE